Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20474664 | 0.77 | L3MBTL1 (0.70) | L3MBTL1MAPTPOLBMAPK1SCN9A | |
| SCHEMBL27076571 | 0.77 | MAPK1 (0.38) | L3MBTL1MAPTMAPK1EPHX2 | |
| SCHEMBL3688798 | 0.76 | HRH3 (0.50) | MAPTCYP2C9CYP2C19KCNH2 | |
| SCHEMBL458559 | 0.75 | L3MBTL1 (1.00) | L3MBTL1MAPTPOLBMAPK1SCN9A | |
| SCHEMBL29488316 | 0.75 | L3MBTL1 (1.00) | L3MBTL1MAPTPOLBMAPK1SCN9A | |
| SCHEMBL1445644 | 0.75 | MAPK1 (0.40) | L3MBTL1MAPK1 | |
| SCHEMBL30914672 | 0.75 | MAPK1 (0.40) | L3MBTL1MAPK1 | |
| SCHEMBL16938414 | 0.74 | GABRP (0.49) | L3MBTL1MAPK1EPHX2 | |
| SCHEMBL4758814 | 0.74 | HDAC1 (0.45) | L3MBTL1MAPTPOLBMAPK1 | |
| SCHEMBL23297258 | 0.74 | CES2 (0.47) | MAPTPOLBMAPK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | L3MBTL1 2733/4885MAPT 581/4885POLB 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.